Literature DB >> 8905249

How important is 24-hour control of blood pressure?

T Morgan1, A Anderson.   

Abstract

Control of blood pressure over the full 24-hour period is important to prevent, or allow resolution of, cardiac and vascular hypertrophy. In addition, the peak incidence of sudden death, myocardial infarction and stroke occurs at the time of the blood pressure increase associated with awakening and arising. There is at present no objective evidence that "good' 24-hour blood pressure control will improve prognosis. Once-daily therapy has created problems in hypertension management. The problem in assessing new drugs was that, in order to achieve blood pressure control before the next drug dose, excessive falls in blood pressure occurred at peak drug concentrations or excessive blood drug concentrations were produced. This led to the concept of a trough: peak ratio. This is not a unique property of a drug and if drugs have an Emax effect (i.e. the drug produces a plateau response) it is dose dependent. Interpreting a trough: peak ratio requires an understanding of the interaction between the pharmacokinetics and pharmacodynamics of a drug. The answer is to use drugs with an elimination half-life close to or greater than the dose interval (24 hours); to use drugs with an "effective' half-life close to or greater than the dose interval, which can be achieved either by modification of the pharmaceutical delivery system or by using drugs that produce a persistent effect because of physiological changes induced; or to give drugs more frequently than once a day. 24-hour blood pressure control is important and the trough: peak ratio of a drug gives a guide as to whether it can be achieved.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8905249     DOI: 10.2165/00002018-199615040-00002

Source DB:  PubMed          Journal:  Drug Saf        ISSN: 0114-5916            Impact factor:   5.606


  20 in total

1.  Twenty-four hour blood pressure profiles in hypertensive patients following various formulations and dosage regimens of felodipine.

Authors:  E Blychert; M Frisén; O Karlsson; L Rydén
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

2.  Prospective evidence of a circadian rhythm for out-of-hospital cardiac arrests.

Authors:  R L Levine; P E Pepe; R E Fromm; P A Curka; P A Clark
Journal:  JAMA       Date:  1992-06-03       Impact factor: 56.272

3.  Relationship of 24-hour blood pressure mean and variability to severity of target-organ damage in hypertension.

Authors:  G Parati; G Pomidossi; F Albini; D Malaspina; G Mancia
Journal:  J Hypertens       Date:  1987-02       Impact factor: 4.844

4.  Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study.

Authors:  D Levy; R J Garrison; D D Savage; W B Kannel; W P Castelli
Journal:  N Engl J Med       Date:  1990-05-31       Impact factor: 91.245

5.  Left ventricular hypertrophy is associated with worse survival independent of ventricular function and number of coronary arteries severely narrowed.

Authors:  R S Cooper; B E Simmons; A Castaner; V Santhanam; J Ghali; M Mar
Journal:  Am J Cardiol       Date:  1990-02-15       Impact factor: 2.778

6.  Antihypertensive effects of beta-blockers administered once daily: 24-hour measurements.

Authors:  J M Neutel; H Schnaper; D G Cheung; W F Graettinger; M A Weber
Journal:  Am Heart J       Date:  1990-07       Impact factor: 4.749

Review 7.  Clinical pharmacokinetics of amlodipine.

Authors:  P A Meredith; H L Elliott
Journal:  Clin Pharmacokinet       Date:  1992-01       Impact factor: 6.447

8.  Clinical pharmacokinetics of nifedipine gastrointestinal therapeutic system. A controlled-release formulation of nifedipine.

Authors:  M Chung; D P Reitberg; M Gaffney; W Singleton
Journal:  Am J Med       Date:  1987-12-21       Impact factor: 4.965

9.  Assessment of the daily blood pressure load as a determinant of cardiac function in patients with mild-to-moderate hypertension.

Authors:  W B White; H M Dey; P Schulman
Journal:  Am Heart J       Date:  1989-10       Impact factor: 4.749

10.  The risk of myocardial infarction associated with antihypertensive drug therapies.

Authors:  B M Psaty; S R Heckbert; T D Koepsell; D S Siscovick; T E Raghunathan; N S Weiss; F R Rosendaal; R N Lemaitre; N L Smith; P W Wahl
Journal:  JAMA       Date:  1995 Aug 23-30       Impact factor: 56.272

View more
  3 in total

Review 1.  Perindopril: an updated review of its use in hypertension.

Authors:  M Hurst; B Jarvis
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 2.  Trandolapril. An update of its pharmacology and therapeutic use in cardiovascular disorders.

Authors:  D C Peters; S Noble; G L Plosker
Journal:  Drugs       Date:  1998-11       Impact factor: 9.546

3.  The association of nocturnal hypertension and nondipping blood pressure with treatment-resistant hypertension: The Jackson Heart Study.

Authors:  Marguerite R Irvin; John N Booth; Mario Sims; Adam P Bress; Marwah Abdalla; Daichi Shimbo; David A Calhoun; Paul Muntner
Journal:  J Clin Hypertens (Greenwich)       Date:  2018-02-13       Impact factor: 3.738

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.